A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)

Grants and Contracts Details

StatusFinished
Effective start/end date10/20/206/15/22

Funding

  • Alexion Pharmaceuticals: $40,542.00